Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Stelara (August Edition)

Active Ingredients: Ustekinumab Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV) Dosage Form: Injection Mechanism of Action: Interleukin 12 & 23 inhibitor First Approval: US (25 Sep, 2009), EU (16 Jan, 2009) Revenue1 Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

BySenior EditorAugust 25, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eliquis (July Edition)

Active Ingredients: Apixaban Strength: 2.5 mg and 5 mg Dosage Form: Tablet Mechanism of Action: Factor Xa inhibitors First Approval: US (Dec 28, 2012), EU (May 18, 2011) Revenue1 Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…

BySenior EditorJuly 28, 2022

VIEWPOINTS

PharmaShots Interview: In Conversation with ViiV Healthcare’s Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV

Shots: Kimberly talked about the approval for label update of ViiV’s lead candidate in HIV, and how an optional oral lead-in will be efficient for people receiving it Kimberly also spoke about ViiV’s collaboration with Janssen for the commercialization of the product The interview gives an understanding of the different treatment options for HIV and…

BySenior EditorJune 29, 2022

INSIGHTS+

Top Performing Drug of 2021 – Revlimid (June Edition)

Active Ingredients: Lenalidomide Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg Dosage Form: Capsules Mechanism of Action: Angiogenic inhibitor First Approval: US (Dec 27, 2005), EU (14 Jun, 2007) Revenue Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…

BySenior EditorJune 23, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in January 2022

The US FDA has approved 3 NDAs and 2 BLAs in Jan 2022, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 5 novel products in 2022 In Jan 2022, the major highlights were Quviviq's approval for insomnia, Cibinqo for atopic dermatitis, Kimmtrak for unresectable or metastatic…

BySenior EditorFebruary 17, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in December 2021

The US FDA has approved 8 NDAs and 1 BLAs in Dec 2021, leading to treatments for patients and advances in the health care industry. The CDER and CBER approved 50 novel products in 2021 In the year 2021, the major highlights were oncology drugs in which 12 out of 50 has approved in oncology,…

BySenior EditorJanuary 27, 2022

VIEWPOINTS

PharmaShots Interview: Impact of new regulations and trends in the medical device industry in India – interviews of Dr. Bina Naik and Dr. Ashish Indani during DIA Medical Device Conference 20

The Medical Devices Conference was hosted by DIA India on 21st and 22nd February in collaboration with the Medical Technology Association of India (MTaI), AIC-AMTZ Medivalley Incubation Council and mDI Europa, is one of the largest gatherings of medical devices professionals in the region. The conference was focused on giving better insights into the challenges…

BySenior EditorJune 22, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2020

The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…

BySenior EditorOctober 29, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2020

The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 13 novel products so far in 2020, including 10 in Feb and 3 in Jan…

BySenior EditorMarch 27, 2020

Top Performing Drug of 2021 – Stelara (August Edition)

Top Performing Drug of 2021 – Eliquis (July Edition)

PharmaShots Interview: In Conversation with ViiV Healthcare’s Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV

Top Performing Drug of 2021 – Revlimid (June Edition)

Insights+: The US FDA New Drug Approvals in January 2022

Insights+: The US FDA New Drug Approvals in December 2021

PharmaShots Interview: Impact of new regulations and trends in the medical device industry in India – interviews of Dr. Bina Naik and Dr. Ashish Indani during DIA Medical Device Conference 20

PharmaShots’ Key Highlights of Third Quarter 2020

Insights+: The US FDA New Drug Approvals in February 2020

Contact US

FOLLOW US